Stock AnalizEncompass Health (EHC) earnings for the quarter ended September 2026: EPS beats estimates
Encompass Health reported results for the quarter ended September 2026 on October 28, 2026. Adjusted earnings per share came in at $1.52 against the analysts’ average forecast of $1.36, a beat of 11.9%.
Revenue for the quarter was $1.61 billion, up 8.9% from $1.48 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 8.2% on the first trading day after the report.
The last four quarters
Encompass Health has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $1.52 | $1.36 | +11.9% | +9% | +8.2% |
| Jun 2026 | $1.55 | $1.48 | +4.8% | +10% | +13.0% |
| Mar 2026 | $1.60 | $1.49 | +7.1% | +9% | +4.8% |
| Dec 2025 | $1.46 | $1.30 | +12.1% | +10% | +10.2% |
What comes next
Analysts expect EPS of $1.61 for the next quarter on average and $6.28 for the fiscal year ending December 31, 2026.
The average analyst price target is $156.08, 11% above the current price of $140.99.
Valuation and score
Encompass Health scores 3.6 out of 5 overall on Stock Analiz (good, with some weak spots), trades at a trailing P/E of about 22.0, and its intrinsic value under moderate assumptions is about 47% below the current market value. Full Encompass Health analysis with 10 years of financials
Frequently asked questions
What was Encompass Health’s EPS for the quarter ended September 2026?
$1.52 adjusted per share, against an analyst consensus of $1.36.
How much revenue did Encompass Health report?
$1.61 billion, up 8.9% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.